Skip to content

Event Details

Seres' news, events and other information can be found throughout the pages below.

Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection Corporate Conference Call

Jul 29, 2016 from 8:30 AM to 8:30 AM EDT